Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics

Cristiano Chaves; Rafael G Dos Santos; Serdar M Dursun; Massimo Tusconi; Mauro Giovanni Carta; Elisa Brietzke; Jaime E C Hallak

doi:10.3389/fpsyt.2024.1485337

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics

Front Psychiatry. 2024 Nov 6:15:1485337. doi: 10.3389/fpsyt.2024.1485337. eCollection 2024.

Authors

Cristiano Chaves¹, Rafael G Dos Santos^{2

3}, Serdar M Dursun^{3

4}, Massimo Tusconi⁵, Mauro Giovanni Carta⁶, Elisa Brietzke¹, Jaime E C Hallak^{2

3

4}

Affiliations

¹ NeuroMood Lab, School of Medicine and Kingston Health Sciences Centre (KHSC), Department of Psychiatry, Queen's University, Kingston, ON, Canada.
² Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
³ National Institute for Translational Medicine (INCT-TM), CNPq, São Paulo, Brazil.
⁴ Department of Psychiatry (Neurochemical Research Unit) and Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
⁵ University Hospital of Cagliari, Cagliari, Italy.
⁶ Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Abstract

Keywords: ayahuasca; dimethyltryptamine (DMT); hallucinogen; neuroplasticity; pharmacology; psychedelics; serotonin 2A (5HT2A) receptor; sigma-1 receptor.

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.